|Day Low/High||126.64 / 128.67|
|52 Wk Low/High||74.51 / 126.48|
If we can advance without China then who the heck knows where we can go with it.
Pets can bring significant profits to companies that cater to this niche market.
Focus on individual stock picking, and take a look at small-caps, as earnings season continues.
The market can still go higher, but the time has come for the slope of price discovery to normalize a bit.
Jim Cramer said that Eli Lilly was the best of the pharmaceutical companies as he looked at the companies reporting earnings this week.
These themes are working despite the turmoil in Washington and slowing global growth.
So far 2019 is proving to be a year where things have a habit of working out right.
Deals that simply were unworkable four months ago because of price are now being done with alacrity.
One of pharma's biggest CEO's talks M&A action on the exchange.
Do we have to run for the hills? Not necessarily.
This is the kind of reversal that happens in a bull market.
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
Pharma companies that have cash are looking at what has happened to this stock market and buying.
Whether this is the end of the slump is still up for debate, but the crash since October has been brutal and all bear markets end the same way.
A close below $105 for the drugmaker's shares would be bearish based on its charts.
Anticipating a weaker dollar thanks to the shift in the Fed, which stocks are most likely to benefit?
Pfizer pushes higher on price increases.
Pharma could be the best parking spot for your money if the market keeps trending downward.
Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.
"We're all hurt someplace and we're all looking for a painkiller." -- Katherine, Looking For Mr. Goodbar As I have previously remarked there is an old trading adage that long trading opportunities often occur in stocks that are green in a sea of red...
Eli Lilly's excellent earnings weren't excellent enough.
Eli Lilly's self-policing on drug pricing protects it from the most prominent political pushbacks.
Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.
LLY's stock slide after earnings might present a buying opportunity.
A bunch of pot stocks are in play on Tuesday -- for a reason.